Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3937-3940

  Zhang, Su Jie ^a   Hu, Yi ^a   Qian, Hai Li ^b   Jiao, Shun Chang ^a   Liu, Zhe Feng ^a   Tao, Hai Tao ^a   Han, Lu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Breast cancer; Estrogen receptor; Progestrone receptor; Tumor markers; Vascular endothelial growth factor

Indexed keywords

EID: 84882613091     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3937     Document Type: Article

References (27)

1. Aktas B, Kasimir-Bauer S, Lehmann N, et al (2013). Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. Oncol Rep, 30, 441-7.
2. Bhattacharjee KG, Bhattacharyya M, Halder UC, et al (2012). The "Cross Talk" between the receptors of insulin, estrogen and progesterone in neutrophils in the synthesis of maspin through nitric oxide in breast cancer. Int J Biomed Sci, 8, 129-39.
3. Bolayirli M, Papila C, Korkmaz GG, et al (2013). Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal, 27, 220-6.
4. Dede DS, Gumuskaya B, Guler G, et al (2013). Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON, 18, 57-63.
5. Deng QQ, Huang XE, Ye LH, et al (2013).Phase II trial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7.
6. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
7. Godfrey AC, Xu Z, Weinberg CR, et al (2013). Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res, 15, R42.
8. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-2800.
9. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.Asian Pac J Cancer Prev, 11, 1059-62.
10. Joensuu K, Leidenius M, Kero M, et al (2013). ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancerreduced CK5 expression in metastases. Breast Cancer (Auckl), 7, 23-34.
11. Lawicki S, Bedkowska GE, Szmitkowski M (2013). VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve. Growth Factors, 31, 98-105.
12. Lee M, Lee CS, Tan PH (2013). Hormone receptor expression in breast cancer: postanalytical issues. J Clin Pathol, 66, 478-84.
13. Luo T, Chen L, He P, et al (2013). Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a chinese population. Asian Pac J Cancer Prev, 14, 2433-7.
14. Omran OM (2012). The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas. J Environ Pathol Toxicol Oncol, 31, 367-76.
15. Patel T, Gupta A, Shah M (2013). Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy. J Cancer Res Ther, 9, 245-9.
16. Petekkaya I, Sahin U, Gezgen G, et al (2013). Association of breast cancer subtypes and body mass index. Tumori, 99, 129-33.
17. Prakhya S, Prakash G (2012). Analysis of BRCA1 gene rearrangements in breast carcinomas by RT-PCR and ER, PR, HER2NEU status by IHC and HPE correlation. J Clin Diagn Res, 6, 1663-8.
18. Rosato V, Bertuccio P, Bosetti C, et al (2013). Nutritional factors, physical activity, and breast cancer by hormonal receptor status. Breast, [Epub ahead of print].
19. Sandoval C, Rahal R, Forte T, et al (2013). Indicator measures er/ pr and her2 testing among women with invasive breast cancer. Curr Oncol, 20, 62-3.
20. Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev, 14, 149-52.
21. Tarhan MO, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9.
22. Thielemann A, Baszczuk A, Kopczynski Z, et al (2013). Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer. Ann Agric Environ Med, 20, 293-7.
23. Vermeulen JF, van der Wall E, Witkamp AJ, et al (2013). Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging. Cell Oncol (Dordr), [Epub ahead of print].
24. Wang J, He Q, Shao YG, et al (2013). Chemokines fluctuate in the progression of primary breast cancer. Eur Rev Med Pharmacol Sci, 17, 596-608.
25. Wang KH, Kao AP, Lin TC, et al (2012). Promotion of epithelialmesenchymal transition and tumor growth by 17ß-estradiol in an ER(+)/HER2(+) cell line derived from human breast epithelial stem cells. Biotechnol Appl Biochem, 59, 262-7.
26. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
27. Zubeda S, Kaipa PR, Shaik NA, et al (2013). Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev, 14, 2231-5.